| Model Number |
9004 |
| Medical Device Problem Code |
Adverse Event Without Identified Device or Use Problem (2993)
|
| Health Effect - Clinical Code |
Reocclusion (1985)
|
| Date of Event |
04/17/2017
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
Analysis: the samples were not returned from the user facility; therefore, device evaluations are unable to be performed.A lot history review revealed 2 additional reocclusion complaints in which 1 is associated with the same patient for this lot.A review of the device history record (dhr) indicates the lot was manufactured to specification.Conclusion: the actual samples were not received for evaluation.The dhr found nothing to indicate a manufacturing related cause for this event.The investigator assessed the event was not related to the study device or procedure.Based on the instructions for use (ifu), the occurrence of reocclusion is an inherent risk of any pta procedure.If additional information becomes known to the manufacturer, a supplemental report will be provided will all relevant information.The information provided by bard represents all of the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to bard.
|
| |
|
Event or Problem Description
|
|
It was reported through a clinical registry that during the index procedure, two lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheters were used to treat the target lesion located in the left mid superficial femoral artery (sfa).Approximately 33 months after the index procedure, the patient¿s left mid sfa vasculature was reportedly reoccluded.A revascularization was performed and the hcp deemed it was successful.The investigator assessed that the event was not related to the study device or procedure.The sample was discarded by the user facility and is not available for evaluation.No adverse patient effects were reported.This is one of two products involved with the reported event and the associated manufacturer's report number is 3006513822-2017-00175.
|
| |
|
Event or Problem Description
|
|
It was reported through a clinical registry that during the index procedure, two lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheters were used to treat the target lesion located in the left mid superficial femoral artery (sfa).Approximately 33 months after the index procedure, the patient¿s left mid sfa vasculature was reportedly reoccluded.A revascularization was performed and the hcp deemed it was successful.The investigator assessed that the event was not related to the study device or procedure.However, the cec adjudicated the study device relationship to be possibly related to the event of reocclusion.The sample was discarded by the user facility and is not available for evaluation.No adverse patient effects were reported.This is one of two products involved with the reported event and the associated manufacturer's report number is 3006513822-2017-00175.
|
| |
|
Additional Manufacturer Narrative
|
|
The event description had the following statement added "however, the cec adjudicated the study device relationship to be possibly related to the event of reocclusion." conclusion the conclusion had the following statement added "however, the cec adjudicated the study device relationship to be possibly related to the event of reocclusion." the samples were not returned from the user facility; therefore, device evaluations are unable to be performed.A lot history review revealed 2 additional reocclusion complaints in which 1 is associated with the same patient for this lot.A review of the device history record (dhr) indicates the lot was manufactured to specification.Conclusion: the actual samples were not received for evaluation.The dhr found nothing to indicate a manufacturing related cause for this event.The investigator assessed the event was not related to the study device or procedure.However, the cec adjudicated the study device relationship to be possibly related to the event of reocclusion.Based on the instructions for use (ifu), the occurrence of reocclusion is an inherent risk of any pta procedure.If additional information becomes known to the manufacturer, a supplemental report will be provided will all relevant information.The information provided by bard represents all of the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to bard.
|
| |
|
Search Alerts/Recalls
|